Navigation Links
New Treatment Combo Better Against Hepatitis C
Date:4/29/2009

Adding antiviral telaprevir increases cure rate, studies show,,,,

WEDNESDAY, April 29 (HealthDay News) -- Adding the antiviral drug telaprevir to standard treatment for hepatitis C increases the cure rate, two new studies show.

Current treatment for hepatitis C (HCV) genotype 1, the most common subtype, is a combination of two drugs, pegylated interferon and ribavirin, given over 48 weeks. This treatment cures less than half of patients and has side effects that make it difficult for some patients to complete the treatment, researchers say. Both reports are published in the April 30 issue of the New England Journal of Medicine.

"Hepatitis C is curable," said the lead researcher of the first study Dr. Jean-Michel Pawlotsky, from the Henri Mondor Hospital, University of Paris, in France. "Currently, 40 to 50 percent of patients infected with HCV genotype 1 can be cured by standard of care, but nothing can be offered to the patients who are unable to eradicate infection on treatment."

For the study, Pawlotsky's team randomly assigned 334 patients with HCV to one of four treatment combinations of telaprevir, peginterferon and ribavirin

The results show that, by using a triple combination of telaprevir, pegylated interferon and ribavirin for 12 weeks, followed by 12 weeks of pegylated interferon and ribavirin, a sustained viral eradication can be achieved in 69 percent of cases, whereas only 46 percent of patients receiving standard of care for 48 weeks achieve a cure, Pawlotsky said.

"This is a breakthrough in HCV therapy," Pawlotsky said. "For the very first time, almost 70 percent cure rates are reached."

These findings open the way to an ongoing phase 3 trial, which could lead to the approval of this combination within the next two years, he said. "The triple combination could become the new standard of care," he noted.

In the second study, Dr. John G. McHutchison, a hepatologist and researcher at Duke University Medical Center, and his colleagues randomly assigned 250 HCV patients to standard treatment or combination therapy with telaprevir, pegylated interferon and ribavirin.

"We managed to cure significantly more patients by adding telaprevir to standard care," McHutchison said. "We cured 50 percent more patients, and we also reduced the duration of treatment from 48 weeks to 24 weeks."

Among patients taking all three drugs, 67 percent were cured compared with 41 percent of patients receiving standard treatment, the Duke researchers found.

McHutchison noted that side effects of pegylated interferon and ribavirin can include flu-like symptoms, depression, fatigue, insomnia and anemia, but adding telaprevir significantly reduces exposure to these drugs, which in turn makes the treatment easier to complete. Twenty-one percent of patients receiving telaprevir did drop out, with rash being the most common reason why.

In addition, 7 percent of the patients developed resistance to telaprevir. "There is an upside and a downside," McHutchison said. "The treatment's shorter, we cure more people, but unfortunately, there are more people who are discontinuing."

There is a phase 3 trial under way, McHutchison said. "If all goes well, this combination could be available in 2011," he said.

"The future looks very bright for people with HCV. Instead of being able to cure less than half of them, we can now, hopefully when these drugs are approved, say to any patient with genotype 1 hepatitis C, we've got a two-out-of-three chance of curing them," McHutchison said.

Dr. Eugene Schiff, chief of the division of hepatology at the University of Miami School of Medicine, thinks these studies are the first step in a major change in HCV treatment.

"Telaprevir represents the type of antiviral therapy for hepatitis C we will see in the future," Schiff said. "In the future, what you are going to see is a mixture of antivirals and my own prediction is you won't see it with interferon and ribavirin," he said.

Schiff thinks these new medications will get more people to go for treatment, because there are fewer side effects and the treatment time is shorter.

In the United States, about 4 million people have HCV, Schiff said. "Most of those people haven't been diagnosed. Of the 1 million who have been diagnosed, maybe 400,000 to 500,000 have been treated, and about 50 percent have been cured," he said.

"If you have an all-oral, highly efficacious regimen with relatively few side effects, then these people who haven't been diagnosed but know they have risk factors are going to come forward, because when they are diagnosed, there is going to be treatment that has a high percentage of cure," Schiff said.

Around the world, 180 million people have HCV. HCV is the leading cause of cirrhosis and liver cancer, and the most common reason for liver transplantation in the United States. HCV is spread mostly by sharing needles.

More information

For more on hepatitis C, visit the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.



SOURCES: John G. McHutchison, M.D., Duke University Medical Center, Durham, N.C.; Jean-Michel Pawlotsky, M.D., Ph.D., Henri Mondor Hospital, University of Paris, France; Eugene Schiff, M.D., chief, division of hepatology, University of Miami School of Medicine; April 30, 2009, New England Journal of Medicine


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New Treatment Discovered for Restless Legs Syndrome Improves Sleep
2. Free Treatment for Breast Cancer Available in Pennsylvania
3. Zebrafish offer clues to treatments for motor neurone disease
4. New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes
5. Varicose Veins Pose Scary Health Risk; Sufferers Find Solace With Insurance-Covered Treatment at Renaissance Laser and Vein Institute
6. Study finds higher drug co-pays discourage patients from starting treatment
7. A Call to Action: NGOs Working in Blindness Prevention and Treatment Convene Special Forum to Address Gender and Eye Health
8. Turtle Island Oxygen Trust Sponsors Free Hyperbaric Treatments
9. Product Shifts are Occurring in the Renal Anemia and Bone and Mineral Metabolism Markets According to the Most Recent TreatmentTrends(R): US Nephrology Report from BioTrends Research Group
10. Different treatment options in chronic coronary artery disease
11. Wyeths CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Treatment Combo Better Against Hepatitis C
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners is ... sequencing and genomics experience, as Vice President of North American Capital Sales at ... for leading the sales team in the commercialization of the HTG EdgeSeq system and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that ... dermaka cream can be incorporated into the post-surgical treatment plans of a variety of ... , dermaka cream is very effective for bruising and causes a rapid resolution of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  The National Pharmaceutical ... joined the health policy research organization as its ... , MD, senior vice president and chief scientific ... representative on the NPC Board of Directors. ... that Mallinckrodt has joined us in support of ...
(Date:6/23/2016)... 2016  Delcath Systems, Inc. (NASDAQ: DCTH ... on treatment of primary and metastatic liver cancers, announces ... - www.againsttheodds.eu - has been awarded a ... The website was developed as ... their families who are coping with the devastating diagnosis ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... ALKS ), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG ), ... BioTech Inc. (NASDAQ: ADRO ). Learn more about ...
Breaking Medicine Technology: